A magnetic anti-cancer compound for magnet-guided delivery and magnetic resonance imaging

Haruki Eguchi, Masanari Umemura, Reiko Kurotani, Hidenobu Fukumura, Itaru Sato, Jeong Hwan Kim, Yujiro Hoshino, Jin Lee, Naoyuki Amemiya, Motohiko Sato, Kunio Hirata, David J. Singh, Takatsugu Masuda, Masahiro Yamamoto, Tsutomu Urano, Keiichiro Yoshida, Katsumi Tanigaki, Masaki Yamamoto, Mamoru Sato, Seiichi InoueIchio Aoki, Yoshihiro Ishikawa

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


Research on controlled drug delivery for cancer chemotherapy has focused mainly on ways to deliver existing anti-cancer drug compounds to specified targets, e.g., by conjugating them with magnetic particles or encapsulating them in micelles. Here, we show that an iron-salen, i.e., μ-oxo N,N'- bis(salicylidene)ethylenediamine iron (Fe(Salen)), but not other metal salen derivatives, intrinsically exhibits both magnetic character and anti-cancer activity. X-Ray crystallographic analysis and first principles calculations based on the measured structure support this. It promoted apoptosis of various cancer cell lines, likely, via production of reactive oxygen species. In mouse leg tumor and tail melanoma models, Fe(Salen) delivery with magnet caused a robust decrease in tumor size, and the accumulation of Fe(Salen) was visualized by magnetic resonance imaging. Fe(Salen) is an anti-cancer compound with magnetic property, which is suitable for drug delivery and imaging. We believe such magnetic anti-cancer drugs have the potential to greatly advance cancer chemotherapy for new theranostics and drug-delivery strategies.

Original languageEnglish
Article number9194
JournalScientific reports
Publication statusPublished - 2015 Mar 17

ASJC Scopus subject areas

  • General


Dive into the research topics of 'A magnetic anti-cancer compound for magnet-guided delivery and magnetic resonance imaging'. Together they form a unique fingerprint.

Cite this